Company
Myrtelle
We are revolutionizing treatment approaches for myelin-based disorders.
Also known as Myrtelle, Inc
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Legal name
- Myrtelle, Inc
- myrtellegtx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
Claim, correct or request removal
Record updated 19 October 2026
About
Myrtelle is a patient-centered, innovation-driven gene therapy company transforming the treatment of neurological diseases. Our mission is to develop and deliver novel treatments for devastating myelin-based disorders of the central nervous system for which few, if any, treatment options exist.
Funding snapshot
- Total raised
- $73.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Undisclosed, $16.7M2026-06-22
Funding rounds
- Round, 2026
- $16.7M2026-06-22, SEC form D sold
- Round, 2025
- $30.5M2025-12-11, SEC form D sold, 21 investors
- Round, 2025
- $7.5M2025-03-12, SEC form D sold, 1 investor
- Round, 2024
- $6M2024-05-21, SEC form D sold, 11 investors
- Round, 2022
- $15.7M2022-10-04, SEC form D sold, 6 investors
- Round, 2021
- $13.5M2021-04-26, SEC form D sold, 27 investors
Loading relationship preview